S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
NASDAQ:LUNG

Pulmonx (LUNG) Stock Forecast, Price & News

$18.16
-0.82 (-4.32%)
(As of 05/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$18.05
$19.03
50-Day Range
$15.59
$27.95
52-Week Range
$15.06
$45.81
Volume
197,489 shs
Average Volume
467,096 shs
Market Capitalization
$674.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.62
30 days | 90 days | 365 days | Advanced Chart
Receive LUNG News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

Pulmonx logo

About Pulmonx

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUNG
Fax
N/A
Employees
253
Year Founded
N/A

Sales & Book Value

Annual Sales
$48.42 million
Book Value
$5.25 per share

Profitability

Net Income
$-48.66 million
Net Margins
-102.87%
Pretax Margin
-103.36%

Debt

Price-To-Earnings

Miscellaneous

Free Float
32,455,000
Market Cap
$674.04 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/03/2022
Today
5/18/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

605th out of 1,426 stocks

Surgical & Medical Instruments Industry

72nd out of 138 stocks

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Pulmonx (NASDAQ:LUNG) Frequently Asked Questions

Is Pulmonx a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Pulmonx stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LUNG, but not buy additional shares or sell existing shares.
View analyst ratings for Pulmonx
or view top-rated stocks.

When is Pulmonx's next earnings date?

Pulmonx is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Pulmonx
.

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) announced its earnings results on Tuesday, May, 3rd. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.06. The business had revenue of $10.79 million for the quarter, compared to analyst estimates of $9.26 million. Pulmonx had a negative net margin of 102.87% and a negative trailing twelve-month return on equity of 26.08%. The firm's revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.34) earnings per share.
View Pulmonx's earnings history
.

What guidance has Pulmonx issued on next quarter's earnings?

Pulmonx updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $55.00 million-$60.00 million, compared to the consensus revenue estimate of $57.84 million.

What price target have analysts set for LUNG?

5 brokers have issued 1-year price objectives for Pulmonx's shares. Their forecasts range from $23.00 to $45.00. On average, they anticipate Pulmonx's share price to reach $31.17 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price.
View analysts' price targets for Pulmonx
or view top-rated stocks among Wall Street analysts.

Who are Pulmonx's key executives?
Pulmonx's management team includes the following people:
  • Mr. Glendon E. French, CEO, Pres & Director (Age 60, Pay $899.58k) (LinkedIn Profile)
  • Mr. David A. Lehman, Gen. Counsel & Sec. (Age 61, Pay $569.14k) (LinkedIn Profile)
  • Mr. Geoffrey Beran Rose, Chief Commercial Officer (Age 49, Pay $524.99k) (LinkedIn Profile)
  • Dr. Derrick Sung Ph.D., Chief Financial Officer (Age 49)
  • Mr. Sri Radhakrishnan, Chief Technical Officer
  • Ms. Lauren Cristina, VP of Fin. & Admin. (U.S.)
  • Ms. Marcee M. Maroney, VP of Marketing (Age 52)
  • Sarah Huber, VP of Sales (U.S.)
  • Mr. Jérôme Erath, Sr. VP & GM of Europe Middle-East & Africa
  • Mr. John B. McKune, VP & Controller (Age 46)
When did Pulmonx IPO?

(LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Pulmonx's stock symbol?

Pulmonx trades on the NASDAQ under the ticker symbol "LUNG."

Who are Pulmonx's major shareholders?

Pulmonx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (14.68%), Deerfield Management Company L.P. Series C (9.96%), BlackRock Inc. (7.44%), Vanguard Group Inc. (7.05%), Champlain Investment Partners LLC (5.90%) and TimesSquare Capital Management LLC (2.89%). Company insiders that own Pulmonx stock include Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III and Scientific Corp Boston.
View institutional ownership trends for Pulmonx
.

Which institutional investors are selling Pulmonx stock?

LUNG stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, TimesSquare Capital Management LLC, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Northern Trust Corp, Metropolitan Life Insurance Co NY, Citigroup Inc., and Royal Bank of Canada. Company insiders that have sold Pulmonx company stock in the last year include David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, and Scientific Corp Boston.
View insider buying and selling activity for Pulmonx
or view top insider-selling stocks.

Which institutional investors are buying Pulmonx stock?

LUNG stock was bought by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, William Blair Investment Management LLC, Primecap Management Co. CA, Goldman Sachs Group Inc., Next Century Growth Investors LLC, Novo Holdings A S, Champlain Investment Partners LLC, and Woodline Partners LP.
View insider buying and selling activity for Pulmonx
or or view top insider-buying stocks.

How do I buy shares of Pulmonx?

Shares of LUNG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmonx's stock price today?

One share of LUNG stock can currently be purchased for approximately $18.16.

How much money does Pulmonx make?

Pulmonx has a market capitalization of $674.04 million and generates $48.42 million in revenue each year. The company earns $-48.66 million in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Pulmonx have?

Pulmonx employs 253 workers across the globe.

What is Pulmonx's official website?

The official website for Pulmonx is pulmonx.com.

How can I contact Pulmonx?

The company can be reached via phone at 650-364-0400 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.